Yazar "Ayer, Mesut" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Cox-2 gene polymorphisms in Turkish patients with myelodysplastic syndrome
    (E-Century Publishing Corp, 2016) Ayer, Mesut; Aktuglu, Mehmet Burak; Acik, Hasan; Bireller, Elif Sinem; Velet, Mustafa; Kirkizlar, Onur; Osmanbasoglu, Emre
    Cyclooxygenase-2 gene polymorphisms have been studied and known its role one on cancerogenesis even though there has not yet been any studies myelodysplastic syndrome. We aimed to provide the first data on COX-2 gene polymorphisms in myelodysplastic syndrome. A total of 39 patients with MDS and 50 healthy controls were recruited from undertaken hematology departmentand compared in terms of COX-2-765 G -> C and COX-2-1195 A. G genes. Statistically significant difference was observed between patients with MDS and controls in terms of COX-2-765 G -> C genotype and distribution of alleles and COX-2-765 GG genotype was more frequently found in the MDS group (P<0.001). Moreover, COX-2-765 C+(CC+CG) genotype was found to provide 5.6 times more protection against MDS. In conclusion, our results indicate that polymorphisms of the C allele of the COX-2 gene may provide protection against MDS; however, its predictive value and potential as a marker in oncology remain to be investigated in further trials.
  • Küçük Resim Yok
    Öğe
    Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis
    (Springer, 2014) Cetin, Guven; Ozkan, Tuba; Turgut, Seda; Cikrikcioglu, M. Ali; Ar, M. Cem; Ayer, Mesut; Unlu, Ayhan
    Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by thrombocytosis with megakaryocytic hyperplasia and thrombocytes are increased with abnormal functions. Discovery of the protein tyrosine kinase JAK2 V617F allele contributed to better understanding of the pathogenetic mechanisms of MPNs. Acquired single point mutation in the JAK2 V617F was determined approximately 50-60 % of patients with ET. In this study we aimed to investigate the relationship between JAK2 V617F gene mutation, hematologic, biochemical markers and the complications in the ET patients. A total of 268 patients diagnosed with ET and 219 of those studied for JAK2 gene mutation were followed at the hematology clinics of three major hospitals between 2008 and 2013 were screened retrospectively. Laboratory, clinical and hematologic parameters were compared for JAK2 V617F positive and JAK2 V617F negative patients with ET. 102 (46 %) patients were positive with the JAK2 V617F mutation. The complications were observed in 61 (28 %) patients and 38 (62 %) of them had JAK2 V617F mutation. The levels of white blood cells, neutrophil, basophil, red blood cells, hemoglobin, hematocrit, mean platelet volume, thrombocytes, eosinophil; urea, creatinine were significantly different in patients with the JAK2 V617F mutation (P < 0.05). Presence of the JAK2 V617F mutation supports the diagnosis of ET. It would be useful to investigate the JAK2 V617F mutation and the hematologic and biochemical markers at diagnosis with respect to consider the risk of developing complications and to take the precautions against these complications.